Arnaldo Negron, MD
Psychiatry · Skillman, NJNPI 1659488138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,559 and has fallen 51.8% since, to $752 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $11.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$628
- AbbVie$460
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$457
- Takeda Pharmaceuticals U.S.A., Inc.$447
- Lundbeck LLC$296
- Axsome Therapeutics, Inc.$280
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,242100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 52 | $628 |
| AbbVie(2 entities) | 76 | $460 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $457 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $447 |
| Lundbeck LLC | 21 | $296 |
| Axsome Therapeutics, Inc. | 20 | $280 |
| Neos Therapeutics, LP | 23 | $241 |
| Sunovion Pharmaceuticals Inc. | 21 | $178 |
| Vanda Pharmaceuticals Inc. | 13 | $175 |
| Teva Pharmaceuticals USA, Inc. | 8 | $146 |
| Novo Nordisk | 8 | $117 |
| Corium, LLC | 11 | $101 |
| Neurocrine Biosciences, Inc. | 5 | $91 |
| Ironshore Pharmaceuticals Inc. | 5 | $68 |
| Avanir Pharmaceuticals, Inc. | 5 | $65 |
| Johnson & Johnson | 5 | $64 |
| Alkermes, Inc. | 4 | $61 |
| Jazz Pharmaceuticals Inc. | 4 | $59 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
| Noven Therapeutics, LLC | 3 | $50 |
| Bausch Health US, LLC | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Neuronetics, Inc. | 2 | $24 |
| Shire North American Group Inc | 2 | $23 |
| Indivior Inc. | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Pernix Therapeutics Holdings, Inc. | 1 | $12 |
How this compares
$4,257 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 36 | $50,731 |
| AuvelityDextromethorphan Hbr/Bupropion | 30 | $45,170 |
| TrintellixVortioxetine Hydrobromide | 39 | $33,565 |
| RexultiBrexpiprazole | 12 | $17,171 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $12,677 |
| Vilazodone Hcl | 64 | $8,694 |
| Bupropion XlBupropion Hcl | 187 | $7,838 |
| Doxepin Hcl | 58 | $5,007 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 116 | $4,419 |
| Aripiprazole | 66 | $3,177 |
| Estazolam | 20 | $2,570 |
| Clonazepam | 150 | $2,338 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $2,292 |
| Nefazodone Hcl | 17 | $2,198 |
| Duloxetine Hcl | 52 | $1,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $460 | $50,73136 claims |
| Axsome Therapeutics, Inc.Auvelity | $280 | $45,17030 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $447 | $33,56539 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $628 | $17,17112 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $65 | $12,67714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Skillman
- Jennifer DismukesSkillman$16K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.